目的 探討仁青芒覺膠囊聯(lián)合雷貝拉唑治療胃潰瘍的臨床療效。方法 選取2020年3月-2023年2月首都醫(yī)科大學(xué)附屬北京康復(fù)醫(yī)院收治的91例胃潰瘍患者,按隨機(jī)數(shù)字表法將所有患者分為對照組(45例)和治療組(46例)。對照組晨服雷貝拉唑鈉腸溶片,20 mg/次,1次/d。治療組在對照組基礎(chǔ)上口服仁青芒覺膠囊,4粒/次,1次/d。兩組療程均為6周。觀察兩組臨床療效,比較治療前后兩組主要癥狀積分、潰瘍愈合率和幽門螺桿菌(Hp)根除率、36項健康調(diào)查簡表(SF-36)評分及血清胃泌素(GAS)、胃動素(MTL)、腫瘤壞死因子-α(TNF-α)、轉(zhuǎn)化生長因子-β1(TGF-β1)水平。結(jié)果 治療后,治療組總有效率是95.65%,較對照組的80.00%顯著提高(P<0.05)。治療后,兩組中上腹痛、反酸、噯氣、脘腹脹滿積分及其總積分均較治療前顯著降低(P<0.05);且治療后,治療組主要癥狀積分顯著低于對照組(P<0.05)。治療后,治療組潰瘍愈合率、Hp根除率分別為73.91%、89.13%,均顯著高于對照組的51.11%、71.11%(P<0.05)。治療后,兩組SF-36中生理健康評分、心理健康評分及量表總分均顯著增加(P<0.05);且治療后,治療組SF-36評分高于對照組(P<0.05)。治療后,兩組GAS、MTL、TNF-α、TGF-β1水平均較治療前顯著下降(P<0.05);且治療后,治療組血清GAS、MTL、TNF-α、TGF-β1水平均顯著低于對照組(P<0.05)。結(jié)論 仁青芒覺膠囊聯(lián)合雷貝拉唑治療胃潰瘍可獲得確切療效,能安全有效地緩解患者主要癥狀,調(diào)節(jié)胃腸激素,抑制炎癥反應(yīng),促進(jìn)潰瘍愈合及Hp清除,改善生活質(zhì)量,值得臨床推廣應(yīng)用。

Objective To explore the clinical efficacy of Renqing Mangjue Capsules combined with rabeprazole in treatment of gastric ulcers. Methods A total of 91 patients with gastric ulcer admitted to Beijing Rehabilitation Hospital Affiliated to Capital Medical University from March 2020 to February 2023 were selected and divided into control group (45 cases) and treatment group (46 cases) according to random number table method. Patients in the control group were po administered with Sodium Rabeprazole Enteric-coated Tablets, 20 mg/time, once daily. Patients in the treatment group were po administered with Renqing Mangjue Capsules on the basis of the control group, 4 grains/time, once daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the score of major symptoms, ulcer healing rate, Hp eradication rate, 36 health survey summary table (SF-36) score and serum gastrin (GAS), motilin (MTL), tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1) levels were compared before and after treatment. Results After treatment, the total effective rate of the treatment group was 95.65%, which was significantly higher than that of the control group (80.00%, P < 0.05). After treatment, the scores of middle and upper abdominal pain, acid regurgitation, belching, abdominal distension and their total scores were significantly decreased in both groups compared with before treatment (P < 0.05). After treatment, the main symptom score of the treatment group was significantly lower than that of the control group (P < 0.05). After treatment, the ulcer healing rate and Hp eradication rate in the treatment group were 73.91% and 89.13%, respectively, which were significantly higher than 51.11% and 71.11% in the control group (P < 0.05). After treatment, the physical health score, mental health score and total score of SF-36 in two groups were significantly increased (P < 0.05). After treatment, the SF-36 score of the treatment group was higher than that of the control group (P < 0.05). After treatment, serum GAS, MTL, TNF-α and TGF-β1 levels in two groups were significantly decreased compared with those before treatment (P < 0.05). After treatment, the levels of GAS, MTL, TNF-α and TGF-β1 in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Renqing Mangjue Capsules combined with rabeprazole can obtain the exact curative effect in treatment of gastric ulcers, can safely and effectively relieve the main symptoms of patients, regulate gastrointestinal hormones, inhibit inflammatory response, promote ulcer healing and Hp clearance, and also can improve the quality of life, which is worthy of clinical application.

R975

首都醫(yī)科大學(xué)附屬北京康復(fù)醫(yī)院科技發(fā)展專項(2020-036)